TMX-67: Treatment of gout and hyperuricemia xanthine oxidase inhibitor

Drugs of the Future

Volumn 26, Issue 1, 2001, Pages 32-38

  Sorbera, L A ^a   Revel, L ^a   Rabasseda, X ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CYANO 4 ISOBUTOXYPHENYL) 4 METHYLTHIAZOLE 5 CARBOXYLIC ACID; ALLOPURINOL; FEBUXOSTAT; UNCLASSIFIED DRUG; XANTHINE OXIDASE INHIBITOR;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL REACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; GOUT; HUMAN; HYPERURICEMIA; PHASE 1 CLINICAL TRIAL; RADIOACTIVITY; REACTION ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035103166     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.01.607802     Document Type: Article

References (32)

1. A facile one-pot synthesis of 4-alkoxy-1,3-benzenedicarbonitrile
2. Asymptomatic hyperuricemia: Risks and consequences in the Normative Aging Study
3. Crystal-associated synovitis
4. Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency
5. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents
6. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549
7. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats
8. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees
9. Allopurinol increases ear swelling and mortality in a dinitrofluorobenzene-induced contact hypersensitivity mouse model
10. Nephrotoxic effects of allopurinol in dinitrofluorobenzene-sensitized mice: Comparative studies on TEI-6720
11. Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice
12. 14C]-TEI-6720, a novel xanthine oxidase inhibitor: Absorption and excretion after intravenous and oral administration in rats
13. 14C]-TEI-6720, a novel xanthine oxidase inhibitor: Tissue distribution after oral administration in rats, protein binding and metabolism in vivo and in vitro
14. Determination of plasma purine nucleoside phosphorylase activity by high-performance liquid chromatography
15. Dose-related decreases in uric acid observed in a multiple-dose safety, pharmacokinetic, and pharmacodynamic study of TMX-67, a novel xanthine oxidase/dehydrogenase inhibitor, in healthy subjects
16. Teijin TAP Holdings sign license agreement for gout therapeutic agent TMX-67
17. TMX-67 development status. Teijin Ltd
18. Hydroxyakalone, a novel xanthine oxidase inhibitor produced by a marine bacterium, Agrobacterium aurantiacum
19. KT651, a new type of hypouricemic agent, has a inhibition on the uric acid biosynthesis and acceleration on uric acid excretion
20. NO production inhibitory and antioxidant constituents from rhubarb - Structural requirements of stilbenes for the activity of plausible mechanism of action
21. Hypouricemic effect of a novel xanthine oxidase (XOD) inhibitor TEI-6720 in rodents
22. New antioxidants with strong free radical scavenging and xanthine oxidase inhibiting activity
23. Hypouricemic activity of Y-700, a new class of xanthine oxidase inhibitor
24. 2-Phenyl-5-thiazolecarboxylic acid derivatives: A new class of potent xanthine oxidase inhibitors
25. Toxic effects of allopurinol on a contact hypersensitivity mouse model
26. Hypouricemic activity of a novel xanthine oxidase/xanthine dehydrogenase (XOD/XDH) inhibitor, TEI-6720 in rats
27. Enzymatic histochemical localization of aldehyde oxidase in rat liver by the tetrazolium method